Vesicular Stomatitis Virus: Veterinary Virology Reference

Overview and Taxonomy of Vesicular Stomatitis Virus (VSV) and the Indiana Serotype (VSIV)

Taxonomic Classification and Nomenclature

Vesicular stomatitis virus (VSV) is the prototypical member of the family Rhabdoviridae, a large and ecologically diverse family of negative-sense, single-stranded RNA viruses that also includes rabies virus (genus Lyssavirus) and numerous plant and fish rhabdoviruses. Within the Rhabdoviridae family, VSV is classified under the genus Vesiculovirus, a group characterized by bullet-shaped virions and a genomic organization that encodes five canonical structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and the large RNA-dependent RNA polymerase (L) [1, 4]. The genus Vesiculovirus encompasses multiple serotypes, of which two principal serotypes, Indiana (VSIV) and New Jersey (VSNJV), have been most extensively studied due to their clinical and economic significance in livestock.

The taxonomic refinement of the Indiana serotype warrants particular attention. Historically referred to as vesicular stomatitis virus Indiana serotype (VSVIND) or simply VSV Indiana, the virus is now formally designated Vesicular stomatitis Indiana virus (VSIV) in accordance with the International Committee on Taxonomy of Viruses (ICTV) guidelines. This reclassification reflects a broader effort to standardize nomenclature across the Rhabdoviridae family, recognizing that VSIV and VSNJV are sufficiently distinct genetically and antigenically to warrant separate species status [4, 12]. The Indiana serotype itself is further subdivided into three subtypes, Indiana 1, Indiana 2 (Cocal virus), and Indiana 3 (Alagoas virus), though Indiana 1 remains the archetype for molecular virology and biotechnology applications [12]. The New Jersey serotype, while sharing the same bullet-shaped morphology and genomic organization, exhibits distinct antigenic properties and epidemiological patterns, underscoring the necessity for serotype-specific diagnostic approaches [7, 13].

Virion Structure and Genome Organization

The VSIV virion is a paradigm of rhabdovirus structural biology. Electron microscopy reveals a characteristic bullet-shaped particle approximately 180 nm in length and 75 nm in diameter, with a helical nucleocapsid core encased within a lipid envelope derived from the host cell plasma membrane [1, 2]. The viral genome consists of a non-segmented, negative-sense RNA molecule of approximately 11,161 nucleotides, as exemplified by the recently constructed synthetic VSV (synVSV) [1]. This compact genome is organized into five transcriptional units arranged in the order 3′-N-P-M-G-L-5′, a gene order that is conserved among vesiculoviruses and is critical for the regulation of viral gene expression. The matrix protein (M) functions as a structural bridge between the nucleocapsid and the envelope, and its predominance in alpha-helical secondary structures facilitates the assembly and budding of progeny virions [2]. The glycoprotein (G) trimer, which forms the characteristic surface spikes visible on the virion envelope, mediates receptor binding and pH-dependent membrane fusion, determinants of viral tropism and entry [7, 10].

One of the most remarkable features of the VSV genome is its modularity and amenability to genetic manipulation. The entire 11.2 kb genome can be assembled from synthetic DNA fragments through reverse genetics, allowing precise modifications such as gene order rearrangement, glycoprotein replacement, or insertion of heterologous transgenes [1, 14]. This genetic plasticity, coupled with the absence of a DNA phase in the replication cycle, positions VSV as a premier platform for both fundamental virology and applied biotechnology.

Epidemiological Context and Host Range

VSV, including the Indiana serotype, is enzootic in tropical and subtropical regions of the Americas, with particularly endemic transmission cycles maintained in Mexico, Central America, and northern South America [3, 7]. The virus is responsible for vesicular stomatitis (VS), a disease of veterinary importance that is clinically indistinguishable from foot-and-mouth disease (FMD) in cattle, swine, and certain other hoofstock. The World Organisation for Animal Health (WOAH) classifies VS as a notifiable disease due to its potential for rapid spread and its capacity to disrupt international trade in animals and animal products. The economic burden is substantial: outbreaks in the United States, occurring sporadically with a roughly decadal periodicity, have involved hundreds of livestock premises across multiple states, precipitating costly quarantines, movement restrictions, and veterinary interventions [3, 7].

The epidemiology of VSV is profoundly shaped by its vector-borne transmission cycle. Unlike many rhabdoviruses that rely on direct contact or fomite transmission, VSV is primarily vectored by hematophagous biting arthropods, including Culicoides biting midges, Simulium black flies, Lutzomyia sand flies, and Aedes mosquitoes [6, 7]. Among these, Culicoides sonorensis has been incriminated as a major vector in the United States, with laboratory studies demonstrating that vector competence is highly temperature-dependent. At constant temperatures of 25–30 °C, which align with the preferred resting temperatures of blood-fed midges, VSV infection rates in both body tissues and salivary glands are significantly elevated compared to those at 20 °C or 35 °C [6]. This thermal optimization benefits both the vector's reproductive fitness and the arbovirus's transmission potential, illustrating a finely tuned ecological coadaptation.

The VSV Platform in Biotechnology and Medicine

Beyond its role as a veterinary pathogen, VSV has emerged as one of the most versatile tools in modern virology. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have recognized VSV-based platforms for their utility in vaccine development and diagnostic applications. The most conspicuous success is the licensed Ebola vaccine, rVSVΔG-ZEBOV-GP (ERVEBO), which is a replication-competent recombinant VSV in which the native glycoprotein (G) is replaced with the Zaire ebolavirus glycoprotein [5, 9]. This vaccine, developed through a public-private partnership, illustrates the translational power of fundamental VSV research: the deep understanding of VSV molecular biology, its rapid replication kinetics, its capacity to accommodate foreign glycoproteins, and its inherent immunogenicity, directly enabled a life-saving product [9].

The adaptability of VSV extends to oncolytic virotherapy, where engineered variants such as HGI627 have been designed with dual-targeting mechanisms. These synthetic viruses incorporate a glycoprotein retargeted to glypican-3 (GPC3) and a genetic ON-switch responsive to β-catenin (CTNNB1), enabling selective lysis of hepatocellular carcinoma cells while sparing normal tissues [10, 14]. The same modular synthetic virology platform that facilitated the construction of synVSV, assembled from four DNA fragments and rescued within weeks, now allows iterative engineering for improved safety and efficacy profiles [1]. Furthermore, pseudotyped VSV particles (VSVΔG) have become standard reagents for serological assays, as they permit the safe, BSL-2-compatible quantification of neutralizing antibodies against high-containment pathogens such as Nipah virus, rabies virus, and SARS-CoV-2 [8, 11, 15].

Diagnostic Differentiation and Serotype Identification

The differential diagnosis of VSV serotypes is essential for outbreak management and epidemiological surveillance. Historically, complement fixation, ELISA, and virus neutralization tests have been employed to distinguish VSIV from VSNJV [12, 13]. More recently, molecular methods such as reverse transcription-polymerase chain reaction (RT-PCR) targeting the phosphoprotein (P) gene have enabled serotype-specific amplification, yielding amplicons of 614 bp for Indiana 1 and 642 bp for New Jersey [12]. The development of rapid immunochromatographic strip tests (ICS) using monoclonal antibodies against the VSIV glycoprotein has further enhanced field-deployable diagnostics, achieving 91.4% sensitivity and 98.9% specificity relative to RT-PCR in clinical trials [13]. Such tools are indispensable for veterinary diagnostic laboratories operating under the WOAH framework, particularly where VS outbreaks mimic FMD and require immediate differentiation to guide control measures.

Molecular Pathogenesis: Matrix Protein Structure, Function, and Viral Assembly

The matrix (M) protein of vesicular stomatitis virus (VSV) represents a paradigm of multifunctionality in viral pathogenesis, orchestrating the critical transition from viral replication to particle morphogenesis and egress. As the most abundant protein within the virion, M serves as the structural linchpin linking the internal ribonucleoprotein (RNP) core, composed of the genomic RNA encapsidated by nucleoprotein (N) and associated with the viral RNA-dependent RNA polymerase (L and P), to the host-derived lipid envelope studded with the trimeric glycoprotein (G) spikes. Beyond its structural role, M is a master regulator of host cell biology, suppressing host gene expression, dismantling the cytoskeleton, and inducing potent cytopathic effects that are central to VSV pathogenesis. A thorough understanding of M protein architecture and its dynamic interactions is therefore indispensable for comprehending both the natural disease cycle of VSV in livestock and the rational design of attenuated vaccine vectors and oncolytic therapeutics.

Primary Structure and Biophysical Characteristics of the VSV Matrix Protein

The M protein of the Indiana serotype (VSIV) is a small, highly basic polypeptide of approximately 229 amino acids, with a molecular weight of roughly 26 kDa [2]. In silico analyses reveal that the protein is overwhelmingly dominated by alpha-helical secondary structures, a feature that confers significant conformational stability and is critical for its multifaceted interactions [2]. The physicochemical properties indicate a protein that is intrinsically membrane-active, possessing distinct hydrophobic patches that facilitate its stable association with the inner leaflet of the plasma membrane, a prerequisite for its function in viral budding. The tertiary structure, validated through rigorous quality assessment methods, is consistent and globular, presenting specific surface-exposed domains for binding to the RNP, the G protein cytoplasmic tail, and host factors [2]. This structural integrity is paramount, as the M protein must precisely coordinate the recruitment of all viral components to the budding site while simultaneously derailing host antiviral responses.

Multifunctional Roles of M Protein in the Viral Life Cycle

Orchestrating Viral Budding and Morphogenesis

The canonical and most extensively characterized function of the M protein is its central role in driving viral assembly and budding. The process is initiated when newly synthesized M molecules, translated on free ribosomes, independently target the inner leaflet of the plasma membrane. Membrane binding is mediated by a combination of electrostatic interactions from its basic N-terminal domain and the insertion of a hydrophobic loop into the lipid bilayer. Once anchored, M functions as a scaffolding protein, laterally associating into a dense, ordered lattice that coats the inner membrane surface. This lattice serves as the recruitment hub for the other structural components: the RNP core (N-RNA template with L and P polymerase) is drawn to the assembly site through specific interactions with the N protein, and the G protein is recruited via its short cytoplasmic tail, ensuring that the nascent particle is studded with the viral entry machinery [2, 16]. The final step of membrane fission and particle release, or pinching-off, is driven by a PPxY late-domain motif within the M protein. This motif recruits components of the host ESCRT (endosomal sorting complexes required for transport) machinery, most notably the Nedd4 ubiquitin ligase, which are commandeered to catalyze the scission event. The absolute quantification of M protein relative to other structural proteins in purified virions, as achieved through advanced UPLC-MRM mass spectrometry, confirms its stoichiometric dominance, underscoring its role as the primary structural building block of the virion [17].

Suppression of Host Gene Expression

A pivotal mechanism underlying the profound cytopathic effect of wild-type VSV is the M protein’s ability to globally inhibit host gene expression. This shutdown occurs at multiple levels, including the inhibition of host transcription (by blocking the function of the TATA-binding protein and TFIID) and, most potently, the inhibition of nucleocytoplasmic transport. M protein achieves this by directly binding to and inducing the degradation of the nuclear pore complex component, Nup98, and by interacting with the Rae1-mRNA export factor. This action effectively paralyzes the host cell's ability to export newly synthesized cellular mRNAs from the nucleus to the cytoplasm for translation. Concurrently, viral mRNAs, which are synthesized and replicated entirely in the cytoplasm by the viral polymerase, continue unabated, giving VSV a dramatic competitive advantage for the translational machinery. This host shutoff function is a major determinant of neurovirulence and systemic spread. Attenuating mutations in the M protein, such as the well-characterized M51 deletion (MΔ51) found in many oncolytic VSV strains, abrogate this host shutoff function, rendering the virus highly sensitive to the host interferon (IFN) response [20]. The MΔ51 mutant serves as a cornerstone for rationally attenuated vaccine vectors and oncolytic platforms, as it retains oncolytic potency in IFN-deficient tumor environments while being profoundly attenuated in normal tissues [20].

Interaction with Host Intrinsic and Innate Immunity

The M protein is also a direct target of host antiviral defenses, highlighting its central importance in the host-pathogen arms race. The interferon-stimulated gene (ISG) product TRIM69 has been identified as a potent and highly specific inhibitor of VSIV infection [4]. TRIM69 directly targets the M protein, and a single amino acid substitution in M can govern the virus's sensitivity or resistance to this restriction factor [4]. This exquisite specificity suggests that the M protein is under intense selective pressure from the host, and that TRIM69 likely interferes with a critical function of M, such as oligomerization, membrane binding, or interaction with host ESCRT components. The high degree of positive selection observed in the human TRIM69 gene reflects a long-standing evolutionary conflict with vesiculoviruses or related pathogens [4]. Furthermore, the ability of the M protein to suppress the interferon signaling cascade by blocking the nuclear translocation of STAT transcription factors is a major virulence determinant. This suppression prevents the establishment of an antiviral state, allowing the virus to replicate to high titers before the host can mount an effective defense.

Engineering the M Protein for Therapeutic Application

The detailed molecular understanding of M protein function has been leveraged extensively for the rational design of recombinant VSV-based vectors. Gene order rearrangement, a powerful tool in synthetic virology, has been used to attenuate the virus by moving the M gene further from the 3’ promoter, thereby reducing its expression level [1]. Because M is the primary viral inhibitor of host gene expression, reducing its abundance diminishes the virus’s ability to shut off the host cell, leading to better innate immune recognition and enhanced safety profiles. This strategy is used in multiple vaccine candidates, including vectors expressing antigens from Nipah, Ebola, and SARS-CoV-2 [5, 9, 18, 19]. Conversely, for oncolytic applications, the MΔ51 mutant is often employed to enhance cancer cell selectivity, as the replication defect is complemented by the defective interferon signaling pathways common in many tumors [10, 14, 20]. More advanced engineering has replaced the entire VSV G protein with heterologous viral glycoproteins, such as those from Nipah virus (F/G), Lyssavirus, or SARS-CoV-2, fundamentally retargeting the virus while retaining the internal structural core, including the M protein, for robust assembly and budding [5, 8, 15]. The pseudotyped VSVΔG system, wherein the G gene is deleted and the M protein drives the assembly of particles bearing foreign glycoproteins, has become an indispensable tool for studying viral entry, screening neutralizing antibodies, and developing vaccines against high-consequence pathogens in a BSL-2 containment setting [8, 11, 15].

Role in Vector-Host-Environment Dynamics

While not directly involved in the environmental dynamics of transmission, the structure and function of the M protein fundamentally determine the viral fitness that underlies its epizootic behavior. The high viral titers achieved in infected livestock, a direct consequence of M-mediated host shutoff, are critical for efficient transmission to the arthropod vectors, primarily Culicoides biting midges, but also mosquitoes, sand flies, and black flies [3, 6, 7]. The ability of VSV to replicate to high levels in the vertebrate host, causing the characteristic vesicular lesions that shed copious virus, is a direct function of the M protein’s powerful replication and egress activities. Furthermore, in the arthropod vector, temperature-dependent replication rates, which influence vector competence and the extrinsic incubation period, ultimately depend on the efficiency of the viral replication complex and the assembly machinery directed by the M protein [6]. Thus, the molecular properties of M are foundational to the ecological and epidemiological patterns observed by organizations such as the WOAH (World Organisation for Animal Health) and the FAO, which monitor the sporadic but economically devastating incursions of VSV from its enzootic foci in Mexico into the United States [3, 12, 13].

Synthetic Virology and Reverse Genetics: Genome Engineering and Rescue of VSV

The capacity to manipulate the genetic blueprint of vesicular stomatitis virus (VSV) has transformed it from a subject of basic virological inquiry into a sophisticated platform for vaccine development, oncolytic therapy, and fundamental studies of viral pathogenesis. The nonsegmented negative-sense RNA genome of VSV, approximately 11,161 nucleotides in length, presents unique challenges and opportunities for genetic engineering. The development of reverse genetics systems, technologies that allow the generation of recombinant viruses from cloned cDNA, has been the cornerstone of this transformation, enabling precise interrogation of viral gene function and the rational design of novel viral vectors [9, 16]. More recently, the emergence of synthetic virology has expanded these capabilities, permitting the de novo assembly and modification of viral genomes with unprecedented speed and flexibility [1, 10].

The Foundational Principles of VSV Reverse Genetics

The genetic economy of the VSV genome, encoding just five structural proteins (N, P, M, G, and L) in a highly conserved order (3′-N-P-M-G-L-5′), belies the complexity of its replication and transcription. Classical reverse genetics for negative-sense RNA viruses relies on the intracellular reconstitution of the viral ribonucleoprotein (RNP) complex. This requires the simultaneous expression of the full-length antigenomic RNA from a plasmid, under the control of a bacteriophage T7 RNA polymerase promoter, along with plasmids encoding the viral nucleoprotein (N), the phosphoprotein (P), and the large polymerase subunit (L). These three proteins constitute the minimal replicase-transcriptase complex necessary for encapsidation, transcription, and replication of the viral genome. The pioneering work that established this system for VSV has become a paradigm for the entire order Mononegavirales [16]. The careful optimization of the ratio of helper plasmids, the inclusion of self-cleaving ribozyme sequences (e.g., from hepatitis delta virus) to generate precise 3′ termini, and the use of cell lines stably expressing T7 RNA polymerase (such as BHK-21 cells infected with a recombinant vaccinia virus expressing T7 or stably transfected cell lines) are all critical parameters for efficient virus rescue [1, 14].

Synthetic Virology: Modular Assembly and Freedom of Design

While classical reverse genetics has been immensely powerful, it is often constrained by the availability of natural restriction enzyme sites, making complex or multi-site modifications laborious and inefficient. Synthetic virology overcomes these limitations by building the viral genome from scratch using chemically synthesized DNA fragments. This approach, as demonstrated by the creation of "synVSV," provides unparalleled freedom of design [1]. In this paradigm, the 11,161 bp genome is subdivided into modular, sequence-verified DNA fragments, often four or more, that can be assembled using techniques like Gibson Assembly or Golden Gate cloning. This modular architecture not only facilitates the initial construction but also simplifies subsequent engineering. For example, Moles et al. (2024) demonstrated that the synVSV platform allowed for the rapid introduction of a foreign glycoprotein and, more strikingly, the rearrangement of the canonical gene order, swapping the positions of the P and M genes [1]. Such a rearrangement, which would be exceedingly difficult using traditional methods, allows researchers to probe the functional significance of gene position on replication kinetics and pathogenicity, as the gradient of transcription from the 3′ to 5′ end dictates relative protein abundance.

Rescue and Phenotypic Characterization of Synthetic Viruses

The rescue of a synthetic virus is not inherently different from a recombinant one, but the verification process is paramount. After the synthetic DNA fragments are assembled into a full-length cDNA clone and transfected into permissive cells (e.g., BHK-21) along with the helper plasmids, the rescued virus must be meticulously characterized. This goes beyond simple titer determination. Comprehensive phenotypic analysis includes comparing the growth kinetics, plaque morphology, and virion particle integrity of the synthetic virus to its natural or wild-type counterpart. Critically, for oncolytic or vaccine applications, the identity of the rescued virus must be confirmed by full-genome sequencing, often using long-read technologies like nanopore sequencing, to rule out any spurious mutations introduced during the assembly or rescue process [1, 14]. The work on synVSV confirmed that a virus built entirely from synthetic oligonucleotides could be phenotypically indistinguishable from the natural virus, validating the fidelity of the approach [1].

Genetic Engineering Strategies for Vaccine and Vector Development

The true power of these technologies lies in their application. Reverse genetics has been harnessed to generate a vast array of recombinant VSVs (rVSVs) for diverse purposes.

Glycoprotein Replacement and Pseudotyping

One of the most common and impactful modifications is the substitution of the native VSV glycoprotein (G) with a glycoprotein from a heterologous virus. This not only alters the tropism of the vector but also renders it replication-defective in a single cycle if the G gene is deleted (VSVΔG). The resulting pseudotyped particles are powerful tools. For instance, VSVΔG particles pseudotyped with Nipah virus (NiV) F and G glycoproteins (rVSVΔG-eGFP-NiVBD F/G) have been generated to study NiV entry mechanisms and serve as a platform for neutralization assays [5, 11]. Similarly, VSV pseudotypes bearing the rabies virus glycoprotein or the SARS-CoV-2 Spike protein have become standard reagents for evaluating neutralizing antibody responses in a BSL-2 setting, avoiding the need to work with the highly pathogenic parent viruses [8, 15]. The licensed Ebola vaccine, rVSVΔG-ZEBOV-GP (ERVEBO), is the most prominent example of this strategy’s translational success, wherein the VSV backbone is rendered safe and immunogenic by expressing the Ebola virus glycoprotein [9].

Multi-Cistronic Vectors and Antigen Expression

VSV’s ability to accommodate additional genetic material has been exploited to create multi-valent vaccines. Foreign genes can be inserted as independent transcription units using cis-acting sequences (e.g., intergenic regions) or by creating fusion proteins. A chimeric vaccine candidate (PHV02) against both Ebola and Nipah viruses has been constructed by inserting the NiV attachment glycoprotein (G) into the rVSV-ZEBOV backbone. This sophisticated vector expresses three viral glycoproteins, VSV G, EBOV GP, and NiV G, and has undergone extensive preclinical safety testing, including the monkey neurovirulence test (MNVT) to assess its neurotropic potential, a critical regulatory hurdle for live vaccines [23].

Attenuation and Safety Engineering

Engineering safety is paramount for clinical applications. Several strategies have been employed to attenuate rVSV vectors. The most common is the truncation of the cytoplasmic tail of the G protein (M51 mutant), which reduces budding efficiency and increases susceptibility to host interferon responses [25, 26]. The synVSV platform has also been used to generate viruses with a matrix protein mutation (MΔ51) to create safer oncolytic backbones [10, 20]. Another powerful approach involves rearranging the gene order to disrupt virulence. Moving the N gene to a more promoter-distal position attenuates the virus by reducing the expression of essential replicase components [16]. Furthermore, the construction of replication-defective, single-cycle VSV vectors, where the G gene is deleted and supplied in trans, provides an inherent safety barrier, as the virus cannot spread beyond the initially infected cell. Such vectors have been shown to induce potent immune responses with a significantly improved safety profile compared to their replication-competent counterparts [19].

Advanced Synthetic Controls: The Genetic ON-Switch

The latest frontier in VSV engineering merges synthetic biology with virology to create "smart" viruses that are only active in specific cellular contexts. Work by Moles and colleagues (2023, 2025) exemplifies this by engineering a synthetic oncolytic VSV (HGI627) with a dual-targeting mechanism. The first level of targeting involves the retargeting of the glycoprotein to a tumor-specific receptor, glypican-3 (GPC3). The second level incorporates a genetic "ON switch", a riboswitch or aptazyme, that controls viral replication in a beta-catenin (CTNNB1)-dependent manner. This means the virus can only replicate efficiently in cells where the Wnt/β-catenin pathway is aberrantly active, a hallmark of many liver cancers. This sophisticated level of control, achieved through the complete synthetic design and assembly of the genome, allows for systemic administration of the virus with dramatically reduced off-target toxicity. In a hepatocellular carcinoma xenograft model, a single dose of HGI627 achieved a 100% complete response, while being well-tolerated even at high multiples of the proposed human dose [10, 14]. This work highlights how the convergence of synthetic biology and reverse genetics is creating therapeutics with precision that was unimaginable a decade ago.

Reverse Genetics as a Diagnostic and Analytical Tool

Beyond basic research and therapeutics, reverse genetics is also crucial for the development of diagnostic reagents. The generation of recombinant viruses expressing fluorescent or luminescent reporter proteins (e.g., GFP, luciferase) enables high-throughput screening for antiviral compounds. Such tools have been used to rapidly quantify the antiviral effects of natural products like resveratrol and curcumin [21, 22, 24], as well as to characterize the mechanism of action of host restriction factors like TRIM69, which was shown to potently inhibit VSV infection [4]. Furthermore, the production of pseudotyped VSV particles with specific envelope proteins provides a standardized, quantifiable reagent for serological surveillance. These pseudotype-based neutralization assays (PNAs) have been validated for Nipah virus and lyssaviruses, offering a safe, rapid, and scalable alternative to traditional virus neutralization tests that require high-containment facilities [8, 11]. The ability to produce these reagents through reverse genetics directly supports global surveillance efforts coordinated by organizations like the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) for diseases of transboundary importance.

Epidemiology and Spatiotemporal Propagation of VSV in the U.S. and Mexico

The epidemiology of vesicular stomatitis virus (VSV) within the North American continent presents one of the most complex and economically impactful vector-borne disease systems in veterinary medicine. Characterized by a distinct enzootic cycle in tropical and subtropical regions of Mexico and a periodic, explosive epizootic pattern that propagates northward into the United States, VSV transmission dynamics are governed by a poorly understood interplay of vector ecology, environmental stochasticity, host population density, and viral serotype-specific fitness landscapes. The disease, which is clinically indistinguishable from foot-and-mouth disease (FMD) in its early stages, imposes severe economic burdens through livestock quarantines, international trade restrictions, veterinary care costs, and lost productivity, making its epidemiological understanding a critical priority for the World Organisation for Animal Health (WOAH) and national veterinary services [7, 12]. This section provides an exhaustive analysis of the spatiotemporal patterns, vector–virus–environment interactions, and modeling frameworks that define VSV propagation across the U.S.–Mexico axis.

Enzootic Maintenance and Epizootic Emergence in Mexico

VSV is considered enzootic throughout much of Mexico, with annual cases occurring in livestock populations, particularly in the coastal lowlands and tropical regions where conditions favor year-round vector activity [3, 7]. The primary serotypes circulating in this region are VSV-New Jersey (VSV-NJ) and VSV-Indiana (VSV-IND), though VSV-NJ is more frequently associated with epizootic spread into the United States [12]. The maintenance cycle in Mexico is believed to involve a complex of sylvatic and domestic vertebrate hosts, with rodents, bats, and wild ungulates potentially serving as reservoir species, though definitive evidence remains elusive due to the challenges of tracing viral persistence in wildlife populations.

The sporadic nature of VSV outbreaks in the southern United States, occurring at intervals of roughly 8 to 12 years, suggests that factors beyond simple viral presence in Mexico are required to trigger a northward incursion [3, 7]. These epizootic events are not merely a function of viral load in enzootic zones but appear to be triggered by specific environmental and ecological conditions that permit the virus to bridge from its maintenance cycle into a transmission cycle capable of sustained geographic expansion. Seasonal patterns in Mexico show peak VSV activity during the rainy season, typically from June through November, coinciding with maximal vector abundance and optimal conditions for viral replication within arthropod vectors [6, 7]. The annual recurrence of cases in Mexican states such as Chiapas, Oaxaca, Veracruz, and Tamaulipas provides a constant source population from which the virus can, under permissive conditions, initiate the multi-state epizootics that threaten U.S. livestock industries.

The Arthropod Vector Complex: Diversity, Ecology, and Competence

A defining characteristic of VSV epidemiology is the remarkable diversity of hematophagous dipteran vectors implicated in its transmission. Unlike many arboviruses that rely on a single or narrow range of vector species, VSV has been isolated from or experimentally transmitted by at least four major taxa: Culicoides biting midges, Lutzomyia sand flies, Simulium black flies, and Aedes mosquitoes [7]. Each of these vector groups possesses distinct ecologies, feeding behaviors, and environmental sensitivities, creating a highly redundant and resilient transmission system that complicates both modeling and control efforts.

Among these, Culicoides sonorensis has received the most rigorous experimental attention in the context of U.S. epizootics. Research by Rozo-Lopez et al. (2022) has demonstrated that C. sonorensis midges exhibit a strong thermal preference for resting at temperatures between 25°C and 30°C after ingesting a VSV-infected blood meal [6]. This temperature range is remarkably congruent with the conditions that optimize both midge fitness and viral replication dynamics. At 25–30°C, midges showed a 66% survival probability by day 10, completed oviposition cycles every 2–3 days, and exhibited the highest rates of VSV infection in both bodies and heads/salivary glands [6]. Crucially, vector competence, defined as the ability to become infected and subsequently transmit the virus, was significantly reduced at both lower (20°C) and higher (35°C) temperatures, indicating that thermal conditions act as a gating mechanism for VSV transmission. The ability of blood-fed midges to behaviorally thermoregulate by selecting resting microhabitats within their preferred thermal range further enhances the alignment of vector physiology and viral replication, effectively creating a "transmission window" that is spatially and temporally constrained.

The implication of Lutzomyia sand flies is particularly relevant for the Mexico–U.S. transmission corridor, as these vectors are more thermophilic and are associated with drier, more xeric environments than Culicoides [7]. Sand flies may play a disproportionate role in bridging VSV from its sylvatic cycle in the Mexican interior to the livestock operations along the northern border. Black flies (Simulium spp.) and Aedes mosquitoes, meanwhile, serve as both mechanical and biological vectors, with black flies being particularly important in high-altitude, fast-flowing water ecosystems common in the Sierra Madre Oriental, a known corridor for northward VSV spread [7]. The existence of multiple, ecologically distinct vector species means that VSV is not constrained by the distribution or abundance of any single vector; rather, the virus can exploit whichever vector community is locally dominant, conferring remarkable epidemiological plasticity.

Spatiotemporal Dynamics of Northward Propagation into the United States

The pattern of VSV entry into the United States is not one of gradual, continuous expansion but rather of intermittent, large-scale outbreak events that typically initiate in the southwestern border states of Texas, New Mexico, and Arizona before spreading north and west into the Rocky Mountain states and occasionally reaching the Pacific coast [3, 7]. The 2019–2020 outbreak, for instance, involved hundreds of affected premises across multiple states and caused severe economic disruption. Understanding the drivers of these episodic incursions has been a central challenge in VSV research, and recent advances in computational modeling are beginning to illuminate the underlying rules.

Rashme et al. (2025) employed a sparse symbolic regression framework, specifically the Sparse Identification of Nonlinear Dynamical Systems (SINDy) algorithm, to identify the ecological variables most predictive of VSV case dynamics across the U.S. and Mexico [3]. This study addressed a critical methodological challenge: the high dimensionality of potential predictors and the zero-inflated nature of case data (many counties reporting no cases). By clustering counties into 40 spatially constrained regions based on static environmental variables, including land cover, soil properties, livestock density, and climate, the researchers created a tractable spatial unit that captured regional ecological heterogeneity while maintaining geographic adjacency constraints [3]. The resulting model demonstrated that graphical features capturing spatial connectivity among regions substantially reduced prediction error compared to models using only ecological covariates. Critically, all best-performing models identified the infected host species composition (cattle, horses, mules) as a key driver of case differences between regions, underscoring the importance of host community structure in propagation dynamics [3].

The temporal resolution of the model revealed that VSV spread is not purely diffusion-driven but exhibits complex, non-linear dynamics where wind patterns, temperature anomalies, and humidity gradients interact with vector dispersal to create "jump" dispersal events, long-range movements that cannot be explained by simple nearest-neighbor contagion [3]. This aligns with field observations that outbreaks can appear hundreds of kilometers from the nearest known infected premises, a pattern consistent with wind-borne transport of infected Culicoides midges. Wind direction and speed, particularly during the spring and summer months when southwesterly flow is dominant, may therefore serve as a critical determinant of outbreak trajectory, potentially explaining why certain years see extensive northward spread while others do not.

The Role of Environmental Temperature in Transmission Cycles

Temperature is perhaps the single most important environmental variable governing VSV epidemiology, exerting effects at every level of the transmission cycle, from vector survival and fecundity to viral replication kinetics and host susceptibility. The work of Rozo-Lopez et al. (2022) provides a mechanistic framework for understanding how temperature acts as a master regulator of vector capacity [6]. At the permissive temperatures of 25–30°C, the extrinsic incubation period (EIP), the time between vector ingestion of a viremic blood meal and the virus reaching the salivary glands in transmissible form, is minimized, while vector survival remains sufficiently high to allow multiple feeding cycles. The coincidence of optimal temperatures for both vector longevity and viral dissemination means that even modest deviations from this range can dramatically reduce the probability of transmission.

At lower temperatures (20°C), blood digestion slows, the interval between feeding cycles lengthens, and viral replication within the midgut is impeded, likely through reduced activity of viral RNA-dependent RNA polymerases and host proteolytic enzymes [6]. At higher temperatures (35°C), although initial viral replication may be rapid, the accelerated metabolism of the vector leads to earlier mortality, reducing the window for transmission. Furthermore, high temperatures can induce cellular stress responses in the midgut epithelium that may enhance antiviral immunity, further suppressing viral titers. The thermal preference displayed by blood-fed midges, seeking out microhabitats at 25–30°C even when maintained at cooler ambient temperatures, suggests a behavioral mechanism that buffers against suboptimal environmental conditions, maintaining transmission potential even in cooler or warmer macroclimates [6]. This behavioral thermoregulation may explain how VSV transmission can persist in the face of diurnal temperature fluctuations that would otherwise disrupt the transmission cycle.

Seasonal temperature patterns across the U.S.–Mexico border region create a distinct transmission season, typically May through October, when mean temperatures fall within the permissive range for vector activity and viral replication. The 2019–2020 outbreak, for example, exhibited a clear seasonal peak in late summer and early autumn, corresponding to the period of maximal vector abundance and optimal thermal conditions [3]. Climate change projections suggest that warming temperatures in the southwestern U.S. could extend the transmission season and shift the geographic range of Culicoides and Lutzomyia vectors northward, potentially increasing the frequency and severity of VSV epizootics in previously unaffected regions.

Host Community Structure and Viral Fitness Landscapes

The distribution and density of susceptible livestock, primarily horses, cattle, and mules, play a critical role in shaping the spatial dynamics of VSV outbreaks. The SINDy modeling approach by Rashme et al. (2025) identified host species composition as a key predictor of regional case dynamics, indicating that the epidemiological landscape is not uniform with respect to host availability [3]. Horses appear to be particularly important sentinel and amplification hosts, as they are highly susceptible to clinical disease and are often the first species to present with vesicular lesions in an outbreak. Cattle, while also susceptible, may exhibit milder or subclinical infections, potentially serving as silent amplifiers that sustain viral circulation without triggering immediate detection. Mules and donkeys, though less common, can also contribute to local transmission [3, 7].

Beyond simple host density, the genetic and immunological heterogeneity of host populations influences viral fitness and adaptation. Experimental evolution studies by Smith-Tsurkan et al. (2010) demonstrated that VSV populations adapting to different mammalian cell types exhibited largely generalist fitness increases, with trade-offs, where adaptation to one host reduces fitness in another, being rare [27]. This finding has profound epidemiological implications: it suggests that VSV is not constrained by fitness trade-offs when moving between host species (e.g., from horses to cattle) or between vector species, allowing it to exploit a wide range of hosts without suffering a loss of replicative capacity. The incongruent fitness landscapes observed across different cell types indicate that the virus can simultaneously improve its performance in multiple environments, a feature that may facilitate rapid adaptation to novel vector or host species encountered during geographic expansion [27]. This generalist capacity, combined with the high mutation rate typical of RNA viruses, means that VSV populations entering the U.S. from Mexico are likely to be highly fit across the diverse host communities they encounter, reducing the probability that host barriers will impede northward spread.

Ecological Drivers and Predictive Modeling Frameworks

The construction of robust predictive models for VSV propagation requires the integration of multiple data streams: vector abundance and phenology, temperature and precipitation records, land cover and soil characteristics, livestock density and movement patterns, and historical case data. The Agglomerative Clustering approach used by Rashme et al. (2025) represents a significant methodological advance, as it groups counties into ecologically coherent regions while preserving spatial adjacency, a critical constraint for modeling contagious processes [3]. The resulting 40 regions, each averaging approximately 90 counties, allowed the researchers to capture regional ecological heterogeneity while reducing the zero-inflation problem inherent in county-level case data.

The inclusion of graph-based features capturing spatial connectivity between regions markedly improved model performance relative to models using only ecological covariates [3]. This finding underscores the importance of spatial network structure in driving VSV dynamics: outbreaks in one region increase the risk of spread to connected regions, with the strength of connectivity mediated by factors such as wind vectors, economic trade routes, livestock movement corridors, and vector dispersal distances. The SINDy framework, by producing sparse, interpretable models with fewer than 11 terms, identified the most parsimonious set of predictors that best explain case dynamics, avoiding overfitting while retaining predictive power [3]. Future iterations of these models could incorporate real-time vector surveillance data, satellite-derived vegetation indices, and livestock movement records to create near-real-time risk forecasting tools analogous to those used for other vector-borne diseases like bluetongue and West Nile virus.

The absence of a mechanistic understanding of the enzootic cycle in Mexico remains a critical gap in predictive capacity. Without knowing which wildlife species serve as reservoirs, how the virus persists between outbreaks, and what environmental triggers initiate spillover into domestic livestock, models of northward propagation are inherently limited in their ability to anticipate the timing and magnitude of epizootics. The sporadic nature of these events, occurring at unpredictable intervals of roughly a decade, suggests that a confluence of rare events (e.g., specific temperature anomalies, vector population explosions, drought-driven host concentration) is required to overcome the barriers that normally restrict VSV to its enzootic range [3, 7]. Resolving the enzootic cycle remains one of the highest priorities for VSV epidemiological research and would represent a transformative advance for the development of evidence-based surveillance and control strategies across the U.S.–México border region.

Diagnostics and Molecular Characterization of VSV Isolates

The accurate and rapid detection of vesicular stomatitis virus (VSV), coupled with comprehensive molecular characterization of field isolates, is paramount for effective disease management, epidemiological surveillance, and the development of safe viral-based therapeutics. As a veterinary pathogen of significant economic consequence and a clinical mimicker of foot-and-mouth disease (FMD), VSV diagnosis necessitates a multi-faceted approach that integrates classical virology with cutting-edge molecular and analytical technologies. The World Organisation for Animal Health (WOAH) recognizes the critical need for differential diagnosis between VSV and FMD, given their clinically indistinguishable vesicular presentations in livestock. This section provides an exhaustive examination of the diagnostic arsenal and molecular characterization techniques applied to VSV isolates, from traditional methods to advanced platforms that define the current landscape of veterinary virology.

Conventional Diagnostic Approaches and Their Limitations

Historically, the diagnosis of VSV has relied upon a triad of classical methods: virus isolation in cell culture, complement fixation (CF), and enzyme-linked immunosorbent assays (ELISA) for antigen detection and serotyping [12]. Virus isolation, typically performed on Vero, BHK-21, or MDBK cell lines, remains a gold standard for obtaining live virus for subsequent characterization. However, this method is time-consuming, requires specialized biosafety facilities (BSL-2/3), and can be hampered by sample degradation or the presence of cytotoxic components. Complement fixation, while useful for serotype differentiation between the New Jersey (NJ) and Indiana (Ind) serotypes, suffers from lower sensitivity and specificity compared to modern immunoenzymatic methods, particularly in samples with anticomplementary activity. Similarly, traditional ELISAs for antigen capture offer improved throughput but can lack the sensitivity required for early detection in subclinical or low-titer infections.

The clinical urgency to differentiate VSV from FMD, a disease for which outbreaks trigger immediate trade sanctions and eradication protocols as mandated by the FAO and WOAH, has driven the development of more rapid and sensitive molecular tools. Reverse transcription-polymerase chain reaction (RT-PCR) has emerged as a cornerstone diagnostic, targeting conserved regions of the VSV genome. One seminal study demonstrated the utility of RT-PCR targeting the NS gene (encoding the phosphoprotein P) for the specific detection and differentiation of VSV-NJ (producing a 642 bp amplicon) and VSV-Ind 1 (producing a 614 bp amplicon) from field samples in Ecuador [12]. This approach offered a significant advantage over CF in terms of speed and sensitivity, with confirmatory sequencing providing definitive identity. The adaptability of RT-PCR has allowed for the development of multiplex assays that can simultaneously detect VSV, FMDV, and other vesicular disease agents, a critical capability for national reference laboratories.

Advanced Serological Characterization: Pseudotype-Based Neutralization Assays

While antigen detection and genome amplification confirm active infection, serological characterization is essential for understanding population immunity, vaccine efficacy, and retrospective surveillance. The use of replication-defective recombinant VSV (rVSV) pseudotypes has revolutionized serological testing, offering a safer, faster, and highly quantitative alternative to traditional virus neutralization tests (VNTs) that require live, wild-type virus. In this system, the VSV glycoprotein gene (G) is deleted (rVSVΔG) and replaced with a reporter gene (e.g., GFP or luciferase). The resulting single-cycle virus is then trans-complemented with the envelope glycoprotein of interest, such as the Nipah virus (NiV) F and G proteins, the Ebola virus (EBOV) GP, or the SARS-CoV-2 spike protein [5, 8, 15, 19]. The pseudotype particles are capable of only a single round of infection, dramatically reducing the biosafety risk and allowing work in BSL-2 facilities.

This platform has been rigorously validated and standardized for assessing neutralizing antibody responses. For example, a pseudotype neutralization assay (PNA) using an rVSV backbone expressing NiV glycoproteins demonstrated 100% sensitivity and specificity, with a strong positive correlation (R² = 0.8461) to a calibrated reference assay [11]. The assay showed excellent dilutional linearity (R² = 0.9940) and high precision, with intra-assay geometric coefficients of variation (GCV) of 6.66% [11]. Similarly, a VSV pseudotype bearing the rabies virus glycoprotein has been developed for the safe and sensitive detection of lyssavirus-neutralizing antibodies, showing strong correlation with the rapid fluorescent focus inhibition test (RFFIT) [8]. These assays are not merely diagnostic tools but are integral to the molecular characterization of the immune response, allowing for the precise quantification of neutralizing antibody titers in International Units (IU) against specific viral glycoproteins. The mechanistic underpinning of these assays lies in the specific interaction between the pseudotype’s envelope glycoprotein and the host cell receptor; inhibition of this interaction by sera antibodies directly correlates with protection.

High-Resolution Molecular Characterization: From Sequencing to Proteomics

Beyond detection and serology, deep molecular characterization of VSV isolates is critical for tracing transmission pathways, identifying virulence determinants, and validating engineered viral backbones for therapeutic use. Next-generation sequencing (NGS) has become the definitive tool for this purpose, enabling full-genome recovery from clinical and laboratory samples. Metagenomic NGS protocols, such as those developed for veterinary diagnostics, allow for the unbiased detection and characterization of VSV without a priori knowledge of the serotype, a significant advantage when dealing with novel or recombinant strains [28]. NGS can resolve minor variant populations within a quasispecies, revealing the evolutionary dynamics that underpin host adaptation and immune evasion.

The application of targeted mass spectrometry, particularly ultra-high-performance liquid chromatography coupled with multiple reaction monitoring (UPLC-MRM), represents a quantum leap in the quantitative proteomic characterization of VSV particles. This technique allows for the absolute quantification of individual viral structural proteins, including the glycoprotein (G), matrix (M), nucleoprotein (N), and the large polymerase (L), using heavy-labeled reference standard peptides [17]. For pseudotyped or chimeric VSV-based therapeutics, such as those incorporating foreign glycoproteins (e.g., VSV-GP), UPLC-MRM is indispensable for monitoring the processing of the envelope glycoprotein precursor (GPC) into its functional subunits (GP1 and GP2) [17]. The ratio of processed to unprocessed glycoprotein is a critical determinant of viral infectivity and fusogenicity. This analytical method provides a level of molecular detail that far surpasses conventional Western blotting, offering precise stoichiometric data that supports product consistency and potency in a regulatory context.

Complementary to proteomics, advanced structural and computational approaches are elucidating the functional architecture of VSV proteins. In silico modeling of the VSV matrix (M) protein, a key driver of viral assembly and budding, reveals a predominance of alpha-helical regions and a consistent tertiary structure, with functional annotations confirming its role in particle morphogenesis [2]. Such analyses, combined with molecular dynamics simulations, can predict how specific mutations, either naturally occurring or engineered, alter protein stability and interactions with host factors. The in-silico prediction of peptide toxicity from the M protein also informs the safety assessment of VSV-based vectors.

Leveraging Synthetic Virology for Molecular Rescue and Characterization

The most transformative advance in VSV characterization is the integration of synthetic virology with rapid diagnostic and analytical pipelines. The ability to chemically synthesize and assemble the entire 11,161 base pair VSV genome from modular DNA fragments has eliminated the dependence on natural isolates for studying viral biology [1]. This synVSV platform enables the rapid engineering of defined genetic changes, including gene rearrangements, glycoprotein swaps, and the insertion of genetic regulatory elements like aptazymes, with unprecedented precision and speed [1, 10, 14]. Following rescue, the identity and genetic stability of these synthetic viruses must be rigorously confirmed. Nanopore sequencing, as highlighted in the development of oncolytic VSV candidates, provides a rapid, real-time method for whole-genome verification, ensuring that the rescued virus matches its intended design and that no spurious mutations have arisen during the rescue process [14].

This synthetic approach directly feeds back into diagnostic method development. For instance, recombinant VSVs expressing fluorescent or luminescent reporter genes (e.g., rVSV-eGFP) are routinely used in high-throughput antiviral screening assays, allowing for the quantitative measurement of viral replication via fluorescence or bioluminescence [21, 22, 24]. The molecular characterization of these reporter viruses is essential to confirm that the inserted transgene is stable and does not attenuate the virus in a way that confounds the assay. Furthermore, synthetic biology platforms are being used to generate precisely defined reference strains and positive controls for RT-PCR and serological assays, ensuring inter-laboratory standardization and traceability.

The characterization of VSV host range and vector competence also relies on molecular tools. Studies on Culicoides sonorensis midges, a primary biological vector, have utilized RT-PCR to quantify VSV infection and dissemination rates in insect bodies and heads under different temperature regimes [6]. Understanding how environmental factors influence viral RNA replication and tissue tropism within the vector is critical for epidemiological modeling and predicting outbreak risk. The molecular detection of VSV in vector populations, coupled with ecological niche modeling that incorporates temperature, precipitation, and livestock density, provides a powerful framework for predicting high-risk zones, a strategy also employed for other vector-borne diseases like bluetongue [3, 29].

Emerging Rapid Diagnostics and Point-of-Care Platforms

The need for field-deployable diagnostics that circumvent the need for laboratory infrastructure has driven the development of lateral flow immunoassays. An immunochromatographic strip (ICS) test utilizing two distinct monoclonal antibodies (MAbs) against the G protein of VSV-Ind has been developed, demonstrating a detection limit of 1.85×10³ TCID₅₀/mL [13]. This test showed a relative specificity of 98.9% and sensitivity of 91.4% compared to RT-PCR in clinical trials, and the strips were stable at room temperature for six months, making them suitable for use in remote livestock markets and farms [13]. The mechanistic basis of this assay involves the formation of a sandwich complex between the colloidal gold-conjugated detection MAb, the viral antigen, and the capture MAb immobilized on the nitrocellulose membrane.

Looking forward, the integration of CRISPR-based diagnostics (e.g., SHERLOCK or DETECTR) with portable fluorescence readers could provide an even more sensitive and specific alternative to lateral flow, with the potential for multiplexed detection of VSV-NJ and VSV-Ind in a single reaction. The ongoing development of comprehensive viral metagenomics and the application of machine learning to interpret propagation dynamics, identifying key ecological variables such as infected species and temperature, represents the next frontier in molecular epidemiology [3, 28]. Ultimately, the convergence of synthetic biology, high-resolution mass spectrometry, and deep sequencing is not only refining our ability to diagnose and characterize VSV but is also reshaping the very definition of what constitutes a viral isolate in the era of precision veterinary virology.

Biotechnological Applications: Vaccine Development, Oncolytic Therapy, and Antiviral Screening

The vesicular stomatitis virus (VSV) has been transformed from a model pathogen of veterinary significance into a highly versatile platform with profound implications for human and animal health. Its simple negative-sense RNA genome, rapid replication kinetics, and ability to accommodate foreign glycoproteins have made it an indispensable tool in vaccine development, oncolytic virotherapy, and antiviral screening. The following sections provide a deep analysis of the biological mechanisms, molecular engineering strategies, and applied outcomes that define VSV’s role in modern biotechnology.

Vaccine Development: Engineering Recombinant Vectors for Emerging and Neglected Pathogens

The development of recombinant VSV (rVSV) as a vaccine vector represents one of the most significant translational achievements in modern virology. The fundamental principle underlying this application is pseudotyping: the VSV glycoprotein (G) gene is replaced with the envelope glycoprotein gene of a target pathogen. This strategy retains VSV’s robust replicative machinery while redirecting its tropism and immunogenicity toward the pathogen of interest.

The most prominent example is the licensed Ebola vaccine, rVSVΔG-ZEBOV-GP (ERVEBO), which replaced the VSV G protein with the Zaire ebolavirus glycoprotein (GP) [9]. This vaccine, developed through a public-private partnership, demonstrated that a replication-competent rVSV vector could provide swift and durable protection against a highly lethal hemorrhagic fever. The success of ERVEBO has established a regulatory and immunological precedent for subsequent rVSV-based vaccines, particularly those targeting Nipah virus (NiV) and SARS-CoV-2. For NiV, which carries a case fatality rate exceeding 70% in some outbreaks and for which no licensed vaccine exists, researchers have constructed a replication-competent rVSVΔG expressing NiV fusion (F) and attachment (G) glycoproteins [5]. This recombinant virus, designated rVSVΔG-eGFP-NiVBD F/G, demonstrated robust replication in multiple cell lines and induced potent neutralizing antibody responses in immunized golden hamsters [5]. The use of a replication-competent platform here is deliberate: it stimulates both humoral and cellular immunity, which is critical for controlling a pathogen known to cause relapsing encephalitis.

A further refinement of this platform involves chimeric vaccines that combine antigens from multiple pathogens. The PHV02 vaccine, for example, is a bivalent rVSV vector encoding both the Ebola virus GP and the Nipah virus G protein [23]. This construction is identical in backbone to ERVEBO, with the addition of the NiV G gene. Safety evaluation of PHV02 required a comprehensive neurovirulence assessment, given that NiV is inherently neurotropic and its ephrin B2/B3 receptors are expressed on neural cells. Intracerebral inoculation of adult hamsters with PHV02 was lethal, whereas the rVSV-EBOV comparator was not [23]. However, the monkey neurovirulence test (MNVT) revealed that PHV02 was significantly less neurovirulent than the yellow fever 17DD vaccine reference control, indicating an acceptable safety profile for human use [23]. These findings underscore the complex phenotypic interplay between the viral vector backbone and the transgenic glycoproteins, a critical consideration for regulatory approval.

The versatility of the VSV platform extends to replication-defective vectors, which offer an enhanced safety profile for immunocompromised individuals. By deleting the VSV G gene entirely, the resulting single-cycle vector is incapable of spreading beyond the initially infected cell. This strategy was applied to a SARS vaccine, where the VSV G gene was replaced with the SARS-CoV S protein [19]. Intramuscular immunization with this replication-defective vector induced a neutralizing antibody response approximately ten-fold greater than that required for protection, and significantly higher than that generated by a replication-competent counterpart [19]. The mechanistic basis for this enhanced immunogenicity likely involves the efficient presentation of the S protein in the context of a single cycle of replication, concentrating antigen production without the confounding effects of viral spread.

The pseudotype platform has also been instrumental for serological surveillance. A validated pseudotyped virus neutralization assay (PNA) using an rVSV backbone has been developed for NiV, allowing the detection of neutralizing antibodies under BSL-2 conditions rather than the BSL-4 containment required for live NiV [11]. This assay demonstrated 100% sensitivity and specificity, with high precision (intra-assay geometric coefficient of variation of 6.66%) and a strong correlation with a calibrated reference assay (R2 = 0.8461) [11]. Similarly, VSV pseudotypes bearing lyssavirus glycoproteins have been developed for the safe and rapid quantification of rabies virus neutralizing antibodies, replacing the traditional rapid fluorescent focus inhibition test (RFFIT) which requires live rabies virus [8]. These assays have direct regulatory and diagnostic utility for vaccine potency testing and epidemiological surveillance.

Oncolytic Therapy: Retargeting, Immune Evasion, and Transcriptional Control

The oncolytic potential of VSV stems from its inherent sensitivity to interferon-mediated antiviral responses. Many cancer cells are defective in interferon signaling, rendering them permissive to VSV replication while normal tissues remain protected. However, natural VSV lacks tumor specificity and can cause neurotoxicity at high doses. The biotechnology challenge has been to engineer VSV variants that are both highly selective for cancer cells and systemically deliverable. Recent advances in synthetic virology have enabled unprecedented precision in achieving these goals.

The development of synthetic VSV (synVSV) platforms represents a paradigm shift. By assembling the 11,161 base pair genome from four modularized DNA fragments, researchers have created a flexible, cost-efficient platform for rapid genetic manipulation [1]. This approach allowed the rearrangement of the entire gene order, swapping the positions of the phosphoprotein (P) and matrix (M) genes, a modification that would be exceedingly difficult with traditional cloning methods [1]. The ability to alter gene order has profound implications for oncolytic therapy, as gene positioning relative to the 3’ promoter directly influences transcription levels. Rearrangement of viral genes can therefore be used to attenuate replication in normal cells while maintaining robust replication in tumor cells.

Dual-targeting strategies have emerged as the most advanced approach to oncolytic VSV design. The virus HGI627 exemplifies this paradigm: it incorporates a synthetic glycoprotein retargeted to glypican-3 (GPC3), a protein highly expressed in hepatocellular carcinoma (HCC), and a beta-catenin (CTNNB1)-dependent aptazyme that functions as a genetic ON switch [10]. The aptazyme is a riboswitch that controls viral replication only when beta-catenin signaling is active, a hallmark of CTNNB1-mutant liver cancers. In vivo, a single intraperitoneal injection of 1×10⁶ TCID₅₀ of HGI627 achieved a 100% complete response in Hep3B xenograft-bearing NSG mice, with a median survival extended to 49 days compared to 15 days in the vehicle group (p < 0.005) [10]. Remarkably, even multiple high-dose administrations (1×10⁹ TCID₅₀) were well tolerated, with no clinical signs of toxicity, representing an equivalent of over 100 times the proposed first-in-human starting dose [10]. This study demonstrates that the combination of retargeted entry and transcriptional control can produce a therapeutic window that is orders of magnitude wider than that of wild-type VSV.

A parallel approach, exemplified by the HG001 virus, targets GPC3 using a retargeted glycoprotein while incorporating a liver cancer-specific aptamer within an aptazyme [14]. In vitro, HG001 showed specific lytic activity in GPC3-positive Huh7 cells at an MOI of 0.1, while GPC3-negative SNU-449 cells and normal NIH/3T3 cells were unaffected even at an MOI of 10 [14]. This represents a selectivity index exceeding 100-fold compared to wild-type VSV, which caused rapid lysis of normal cells at an MOI of 0.01 [14]. The mechanistic basis for this selectivity lies in the combined failure of the aptazyme to activate in cells lacking beta-catenin signaling and the inability of the retargeted glycoprotein to mediate entry into cells lacking GPC3.

Beyond retargeting, oncolytic potency can be enhanced by engineering the virus to evade the host antiviral inflammatory response. The innate immune system, particularly natural killer (NK) cells and inflammatory cytokines, represents a major barrier to intratumoral virus spread. To overcome this, a recombinant VSV was engineered to express the equine herpesvirus-1 glycoprotein G, a broad-spectrum viral chemokine binding protein (rVSV-gG) [25]. In a syngeneic rat model of multifocal HCC, infusion of rVSV-gG via the hepatic artery resulted in a 1-log enhancement in intratumoral virus titer compared to a reference rVSV vector, with a corresponding reduction in NK and NKT cell infiltration into tumors [25]. This led to increased tumor necrosis and substantially prolonged animal survival without toxicities [25]. This strategy highlights a critical insight: the virus’s own oncolytic activity is often limited by the very immune response it triggers, and vector-mediated suppression of that response can exponentially enhance therapeutic efficacy.

Experimental evolution has also been used to adapt VSV to specific cancer genotypes. By passaging VSV in p53-knockout mouse embryonic fibroblasts (p53-/- MEFs), researchers evolved viral lineages with increased fitness and cytotoxicity in p53-deficient cells, but not in isogenic p53+/+ cells [20]. This gene-specific adaptation was confirmed by EC50 assays showing that evolved viruses were more effective against p53-deficient 4T1 breast cancer cells than the parental virus or the reference oncolytic strain MΔ51 [20]. In vivo, one evolved line significantly delayed tumor growth in a 4T1 syngeneic model compared to controls [20]. These results demonstrate that RNA viruses can be specifically adapted to common cancer hallmarks such as p53 inactivation, offering a complementary approach to rational design.

The quantitative characterization of oncolytic VSV particles is itself a biotechnological challenge. A UPLC-MRM mass spectrometry method has been developed for the absolute quantification of structural proteins in pseudotyped VSV-GP particles, a new biotherapeutic platform [17]. This assay can simultaneously quantify the processed GP1 and GP2 subunits of the envelope glycoprotein, as well as any remaining unprocessed full-length GPC, providing a critical quality attribute for manufacturing [17]. The complete processing of GPC is a prerequisite for infectivity, and this analytical method enables tracking of processing efficiency in production cell lines such as HEK-293-F [17].

Antiviral Screening: Platforms for Natural Product Discovery and Host Factor Identification

The use of VSV in antiviral screening is historically rooted in its high sensitivity to interferon and its utility as a reporter virus. More recently, synthetic biology and pseudotype platforms have expanded the scope and throughput of screening efforts, enabling the identification of both direct-acting antivirals and host-directed therapies.

The synthetic virology platform has accelerated antiviral screening by allowing the rapid construction of VSV variants bearing foreign glycoproteins. This is critical for screening entry inhibitors against emerging viruses without requiring high-containment facilities. For example, the VSVΔG pseudotype system was used to generate SARS-CoV-2 spike-bearing particles for studying viral entry and screening neutralizing antibodies [15]. This system, which can produce pseudovirus and complete an infection assay within one week, demonstrated efficient infection of human 293T, Calu-3, and Vero-E6 cells, as well as human induced pluripotent stem cell-derived cardiomyocytes [15]. The ability to rapidly switch the glycoprotein makes VSV an ideal platform for screening against multiple viral families, including lyssaviruses, filoviruses, and coronaviruses.

Natural product screening using VSV has yielded several promising candidates. The water extract of the marine alga Sarcodia suae (SSWE) demonstrated potent antiviral activity against VSV, with an EC50 of 0.422 ± 0.14 mg/ml and no detectable cytotoxicity [21]. Mechanistic studies revealed that SSWE interferes with multiple stages of the VSV life cycle, including viral attachment, entry, RNA replication, and egress, and also reduces VSV-induced autophagy in Mv1Lu cells during late infection [21]. The identification of a marine algal extract with multi-stage antiviral activity is significant, as it suggests the presence of synergistic bioactive compounds that could be developed into a veterinary therapeutic.

Resveratrol, a natural polyphenol found in grapes and berries, has also been shown to suppress VSV infection in vitro [22]. Using a recombinant VSV expressing GFP, resveratrol treatment reduced viral replication, as indicated by a decrease in fluorescent signal, and increased cell viability [22]. The antiviral mechanism was linked to suppression of the caspase cascade, with structural analysis suggesting that resveratrol may interact with the active sites of caspase-3 and -7 [22]. This is a notable divergence from the direct-acting mechanisms of many antivirals, highlighting the potential for host-directed therapies that modulate apoptosis pathways to limit viral cytopathology.

Curcumin, the active polyphenol in turmeric, provides another example of a natural product with anti-VSV activity. At a concentration of 10 μM, curcumin provided robust inhibition of VSV-EGFP infection in Vero cells, with approximately 33% reduction at an MOI of 0.0002 and nearly 90% reduction at an MOI of 0.00002 [24]. Interestingly, curcumin treatment was associated with increased expression of Dicer-1, a key enzyme in the RNA interference pathway, suggesting that VSV infection may itself suppress Dicer-1 expression and that curcumin’s antiviral effect could involve rescue of this innate antiviral mechanism [24]. The antioxidant properties of curcumin may also play a role, as VSV infection induces oxidative stress to promote apoptosis.

Immunomodulators offer a different class of antiviral. Glutoxim (GLT), a known immunomodulator, was tested against VSV in diploid fibroblast cell lines. At low doses (0.1–0.5 mg/ml), GLT led to a significant (more than 100-fold) inhibition of VSV replication 24 hours post-infection, although this effect was not sustained at later time points [18]. This transient activity suggests that GLT acts through early induction of an antiviral state rather than through direct virucidal activity, consistent with its immunomodulatory function.

The identification of host restriction factors is another critical application of VSV in antiviral screening. TRIM69, an interferon-stimulated gene (ISG), was identified through arrayed ISG expression screening as a potent and specific inhibitor of vesicular stomatitis Indiana virus (VSIV) [4]. The inhibition was highly specific: influenza A virus, HIV-1, Rift Valley fever virus, and dengue virus were all unaffected by TRIM69 [4]. Remarkably, a single amino acid substitution in VSIV was sufficient to govern sensitivity or resistance to TRIM69, demonstrating the extreme specificity of this restriction factor [4]. TRIM69 is highly divergent in human populations and exhibits signatures of positive selection, consistent with a key role in antiviral immunity [4]. This finding has direct implications for the safety and efficacy of VSV-based therapies, as TRIM69 expression levels in target tissues may influence viral replication and spread.

The interferon-induced block of VSV mRNA capping provides a classical example of the molecular underpinnings of the antiviral state. Interferon treatment of HeLa cells results in a significant increase in the concentration of S-adenosylhomocysteine (AdoHcy), a competitive inhibitor of viral mRNA methyltransferases [30]. The AdoHcy/AdoMet ratio increases more than 2-fold, leading to preferential inhibition of the viral (guanine-7-)methyltransferase activity [30]. This results in the synthesis of VSV mRNA lacking the 7-methyl group on the 5’-terminal guanosine cap, rendering these transcripts translationally inactive [30]. This mechanism provides a biochemical basis for the profound interferon sensitivity of VSV and explains why many cancer cells, which have defective interferon responses, are permissive to oncolytic VSV replication.

Finally, the use of VSV in high-throughput antiviral screening is facilitated by the development of standardized assays. The pharmacopoeial reference standard for recombinant human interferon α-2b potency testing relies on inhibition of VSV-induced cytopathic effect in A-549 and MDBK cell lines [31]. This assay, which has been certified according to international standards, ensures that interferon products used in both human and veterinary medicine have consistent antiviral activity [31]. The reliance on VSV for such regulatory bioassays underscores the virus’s status as a reference pathogen for antiviral testing.

References

[1] Moles CM, Basu R, Weijmarshausen P, Ho B, Farhat M, Flaat T, et al.. Leveraging Synthetic Virology for the Rapid Engineering of Vesicular Stomatitis Virus (VSV). bioRxiv. 2024. DOI: https://doi.org/10.1101/2024.09.26.615165

[2] S R, R SV, R PS, Prabhu P. In-Silico Approaches for Molecular Characterization, Structural Function Prediction and Peptide Toxicity Analysis of the Matrix Protein of Vesicular stomatitis Indiana Virus (VSIV). BIO Web of Conferences. 2025. DOI: https://doi.org/10.1051/bioconf/202517202007

[3] Rashme T, Zhang Z, Weeks J, Benbrahim M, Zhang Z, Chen Z, et al.. Graph symbolic regression to interpret the propagation of Vesicular Stomatitis Virus across the U.S. and Mexico. SIGSPATIAL/GIS. 2025. DOI: https://doi.org/10.1145/3748636.3764166

[4] Rihn SJ, Aziz MA, Stewart DG, Hughes J, Turnbull ML, Varela M, et al.. TRIM69 Inhibits Vesicular Stomatitis Indiana Virus. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00951-19

[5] Guo H, Liu R, Pan D, Dang Y, Meng S, Shan D, et al.. Development and Immunogenic Evaluation of a Recombinant Vesicular Stomatitis Virus Expressing Nipah Virus F and G Glycoproteins. Viruses. 2025. DOI: https://doi.org/10.3390/v17081070

[6] Rozo-Lopez P, Park Y, Drolet B. Effect of Constant Temperatures on Culicoides sonorensis Midge Physiology and Vesicular Stomatitis Virus Infection. Insects. 2022. DOI: https://doi.org/10.3390/insects13040372

[7] Rozo-Lopez P, Drolet B, Londoño-Renteria B. Vesicular Stomatitis Virus Transmission: A Comparison of Incriminated Vectors. Insects. 2018. DOI: https://doi.org/10.3390/insects9040190

[8] Moeschler S, Locher S, Conzelmann K, Krämer B, Zimmer G. Quantification of Lyssavirus-Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudotype Particles. Viruses. 2016. DOI: https://doi.org/10.3390/v8090254

[9] Anderson EM, Coller B. Translational success of fundamental virology: a VSV-vectored Ebola vaccine. Journal of Virology. 2024. DOI: https://doi.org/10.1128/jvi.01627-23

[10] Moles CM, Basu R, Ho B, Farhat M, Kent J, Weijmarshausen P, et al.. Abstract 946: Novel oncolytic virus targeting GPC3 and CTNNB1 demonstrates complete response in hepatocellular carcinoma (HCC) xenograft with a single, systemic administration. Cancer Research. 2025. DOI: https://doi.org/10.1158/1538-7445.am2025-946

[11] Alam M, Rana MJ, Salauddin A, Bentley E, Kamuyu G, Shill DK, et al.. Development and Validation of a Standardized Pseudotyped Virus-Based Neutralization Assay for Assessment of Anti-Nipah Virus Neutralizing Activity in Candidate Nipah Vaccines. Vaccines. 2025. DOI: https://doi.org/10.3390/vaccines13070753

[12] Sepulveda L, Malirat V, Bergmann I, Mantilla A, Nascimento ER. Rapid diagnosis of vesicular stomatitis virus in Ecuador by the use of polymerase chain reaction. Brazilian Journal of Microbiology. 2007. DOI: https://doi.org/10.1590/S1517-83822007000300022

[13] Sun C, Zhao K, Chen K, He W, Su G, Sun X, et al.. Development of a convenient immunochromatographic strip for the diagnosis of vesicular stomatitis virus serotype Indiana infections.. Journal of Virological Methods. 2013. DOI: https://doi.org/10.1016/j.jviromet.2012.12.003

[14] Moles C, Basu R, Flaat T, Collado C, Weijmarshausen P. Abstract 688: Oncolytic VSV with retargeted glycoprotein and genetic ON switch for precise targeting of liver cancer using a synthetic virology platform. Cancer Research. 2023. DOI: https://doi.org/10.1158/1538-7445.am2023-688

[15] Capcha JMC, Lambert G, Dykxhoorn D, Salerno A, Hare J, Whitt M, et al.. Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. Frontiers in Cardiovascular Medicine. 2021. DOI: https://doi.org/10.3389/fcvm.2020.618651

[16] Munis AM, Bentley E, Takeuchi Y. A tool with many applications: vesicular stomatitis virus in research and medicine. Expert Opinion on Biological Therapy. 2020. DOI: https://doi.org/10.1080/14712598.2020.1787981

[17] Basu R, Dambra R, Jiang D, Schätzlein SA, Njiyang S, Ashour J, et al.. Absolute Quantification of Viral Proteins from Pseudotyped Vesicular Stomatitis Virus (VSV-GP) using Ultra High-Performance Liquid Chromatography- Multiple Reaction Monitoring (UPLC-MRM). bioRxiv. 2023. DOI: https://doi.org/10.1101/2023.10.09.561556

[18] Ожерелков С, Ozherelkov S, Кожевникова Т, Kozhevnikova TN, Санин А, Sanin A, et al.. Study of Glutoxim antiviral activity in the fibroblast cell line infected with vesicular stomatitis virus. Russian veterinary journal. 2018. DOI: https://doi.org/10.32416/ARTICLE_5C050AC0894B34.21127720

[19] Kapadia SU, Simon ID, Rose J. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology. 2008. DOI: https://doi.org/10.1016/j.virol.2008.03.002

[20] Garijo R, Hernández‐Alonso P, Rivas C, Diallo J, Sanjuán R. Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0102365

[21] Chang T, Lin C, Wu S, Lin L, Lai P, Liao C, et al.. Antiviral effects of Sarcodia suae water extracts against vesicular stomatitis virus infection. European journal of phycology. 2024. DOI: https://doi.org/10.1080/09670262.2024.2405614

[22] Lin S, Zhang X, Lehman C, Pan H, Wen Y, Chen S. A Natural Botanical Product, Resveratrol, Effectively Suppresses Vesicular Stomatitis Virus Infection In Vitro. Plants. 2021. DOI: https://doi.org/10.3390/plants10061231

[23] Monath T, Nichols R, Tussey L, Scappaticci K, Pullano T, Whiteman M, et al.. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathogens. 2022. DOI: https://doi.org/10.1371/journal.ppat.1010658

[24] Ahmed J, Tan Y, Ambegaokar SS. Effects of Curcumin on Vesicular Stomatitis Virus (VSV) Infection and Dicer‐1 Expression. The FASEB Journal. 2017. DOI: https://doi.org/10.1096/fasebj.31.1_supplement.622.11

[25] Altomonte J, Wu L, Chen L, Meseck M, Ebert O, García‐Sastre A, et al.. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.. Molecular Therapy. 2008. DOI: https://doi.org/10.1038/SJ.MT.6300343

[26] Johnson JE, Coleman J, Kalyan N, Calderon P, Wright K, Obregon J, et al.. In vivo Biodistribution of a Highly Attenuated Recombinant Vesicular Stomatitis Virus Expressing HIV-1 Gag Following Intramuscular, Intranasal, or Intravenous Inoculation. Vaccine. 2009. DOI: https://doi.org/10.1016/j.vaccine.2009.03.006

[27] Smith-Tsurkan SD, Wilke C, Novella I. Incongruent fitness landscapes, not tradeoffs, dominate the adaptation of vesicular stomatitis virus to novel host types. Journal of General Virology. 2010. DOI: https://doi.org/10.1099/vir.0.017855-0

[28] Kubacki J, Fraefel C, Bachofen C. Implementation of next-generation sequencing for virus identification in veterinary diagnostic laboratories. Journal of Veterinary Diagnostic Investigation. 2020. DOI: https://doi.org/10.1177/1040638720982630

[29] Acosta A, Barrera M, Jarrín D, Maldonado A, Salas J, Camargo G, et al.. Linking vector favourable environmental conditions with serological evidence of widespread bluetongue virus exposure in livestock in Ecuador. Scientific Reports. 2025. DOI: https://doi.org/10.1038/s41598-025-95918-7

[30] Ferra Fd, Baglioni C. Increase in S-adenosylhomocysteine concentration in interferon-treated HeLa cells and inhibition of methylation of vesicular stomatitis virus mRNA.. Journal of Biological Chemistry. 1983. DOI: https://doi.org/10.1016/S0021-9258(18)32894-1

[31] Gaiderova LA, Lebedeva YN, Lobanova T, Lipatova EK, Volkova RA, Fadeikina OV. Certification of a pharmacopoeial reference standard for potency testing of recombinant interferon α-2b. Biological Products. Prevention, Diagnosis, Treatment. 2024. DOI: https://doi.org/10.30895/2221-996x-2024-24-1-21-31